All In Biotech

Drug Trial Radar · NCT06586866

JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases

A Multicenter, Single-Arm, Phase 2 Study to Evaluate the Safety, Efficacy and Pharmacokinetics of JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases

Last checked: Nov 20, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

25

Planned (sponsor's estimate)

Start

Sep 26, 2024

Primary completion

May 26, 2026

Study completion Oct 26, 2026

Sponsor

Lead sponsor
JenKem Technology Co., Ltd.Industry
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was designed to evaluate the safety, efficacy and pharmacokinetics of JK-1201I in triple negative breast cancer patients with brain metastases.

Conditions

  • Triple Negative Breast Cancer (TNBC)
  • Brain Metastasases

Interventions

  • JK-1201IDrug

    JK-1201I will be administered as an IV infusion at dose of 125mg/m2 on Day 1 of each 14-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) according to RECIST 1.1 and RANO-BMTime frame: Up to approximately 12 months.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.